Preparation of Structurally Modified Plumbagin Silver Nanoparticle for its Prospective Binding to Trastuzumab
DOI:
https://doi.org/10.52783/jns.v14.2282Keywords:
Antibody conjugation, Plumbagin, TrastuzumabAbstract
Combination therapy plays a major part in reducing side effects in treatment of breast cancer. For treating HER2-positive breast cancer, HER2-targeted therapy is common. A natural compound, Plumbagin, gives activity against the HER2 receptor that can be employed in breast cancer therapy. A conjugation of plumbagin with Trastuzumab increases its targeting specificity to the HER2 receptor. However, the low stability of plumbagin necessitates an encapsulation in silver nanoparticles (AgNPs) to widen its stability and therapeutic efficacy. This study using Nano-precipitation technique, the silver nanoparticles were synthesized in varying concentrations of polyvinylpyrrolidone (PVP), silver nitrate, and sodium borohydride. The parameters of formulations are particle size, polydispersity index (PDI), and zeta potential, were optimized through statistical analysis by QBD design. Based on these parameters, a best formulation was selected. The successful loading of Plumbagin into the nanoparticles attained 85% entrapment efficiency. The release kinetics of the drug within 24 hours was approximately 89%. Nanoparticles were structurally modified with carbonyl groups to facilitate the conjugation with Trastuzumab, also this promotes attachment of the monoclonal antibody through its amine group. Scanning electron microscopy (SEM), Transmission electron microscopy (TEM), and Fourier-transform infrared (FTIR) spectroscopy tools recorded the confirmation of surface conjugation. This approach ensures a obligation strategy for the target delivery and also stability of plumbagin.
Downloads
Metrics
References
Bhavsar DB, Patel V, Sawant KK. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy. European Journal of Pharmaceutical Sciences. 2020 Sep 1;152:105428.
Deken MM, Kijanka MM, Hernández IB, Slooter MD, de Bruijn HS, van Diest PJ, en Henegouwen PM, Lowik CW, Robinson DJ, Vahrmeijer AL, Oliveira S. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. Journal of controlled release. 2020 Jul 10;323:269-81
Solanki R, Saini M, Mochi J, Pappachan A, Patel S. Synthesis, characterization, in-silico and in-vitro anticancer studies of Plumbagin encapsulated albumin nanoparticles for breast cancer treatment. Journal of Drug Delivery Science and Technology. 2023 Jun 1;84:104501.
Rahmani F, Imani Fooladi AA, Ajoudanifar H, Soleimani NA. In silico and experimental methods for designing a potent anticancer arazyme-herceptin fusion protein in HER2-positive breast cancer. Journal of Molecular Modeling. 2023 May;29(5):160.
Leung JH, Tai YS, Wang SY, Fion HT, Tsung-Chin H, Chan AL. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer. The Breast. 2022 Oct 1;65:91-7.
Moors E, Sharma V, Tian F, Javed B. Surface-Modified Silver Nanoparticles and Their Encapsulation in Liposomes Can Treat MCF-7 Breast Cancer Cells. Journal of Functional Biomaterials. 2023 Oct 11;14(10):509.
Dinparvar S, Bagirova M, Allahverdiyev AM, Abamor ES, Safarov T, Aydogdu M, Aktas D. A nanotechnology-based new approach in the treatment of breast cancer: Biosynthesized silver nanoparticles using Cuminum cyminum L. seed extract. Journal of Photochemistry and Photobiology B: Biology. 2020 Jul 1;208:111902.
Beg S, Swain S, Rahman M, Hasnain MS, Imam SS. Application of design of experiments (DoE) in pharmaceutical product and process optimization. InPharmaceutical quality by design 2019 Jan 1 (pp. 43-64). Academic Press.
Jarullah A, Mohammed HJ. Experimental Design of Oxidative Desulfurization of Kerosene Through Response Surface Methodology (RSM). Tikrit Journal of Engineering Sciences. 2023 Jul 30;30(2):130-41.
Jankovic A, Chaudhary G, Goia F. Designing the design of experiments (DOE)–An investigation on the influence of different factorial designs on the characterization of complex systems. Energy and Buildings. 2021 Nov 1;250:111298.
Ratan ZA, Haidere MF, Nurunnabi MD, Shahriar SM, Ahammad AS, Shim YY, Reaney MJ, Cho JY. Green chemistry synthesis of silver nanoparticles and their potential anticancer effects. Cancers. 2020 Apr 1;12(4):855.
Dinparvar S, Bagirova M, Allahverdiyev AM, Abamor ES, Safarov T, Aydogdu M, Aktas D. A nanotechnology-based new approach in the treatment of breast cancer: Biosynthesized silver nanoparticles using Cuminum cyminum L. seed extract. Journal of Photochemistry and Photobiology B: Biology. 2020 Jul 1;208:111902.
Rajkumar V, Gunasekaran C, Paul CA, Dharmaraj J. Development of encapsulated peppermint essential oil in chitosan nanoparticles: Characterization and biological efficacy against stored-grain pest control. Pesticide Biochemistry and Physiology. 2020 Nov 1;170:104679.
Tan G, Kantner K, Zhang Q, Soliman MG, Del Pino P, Parak WJ, Onur MA, Valdeperez D, Rejman J, Pelaz B. Conjugation of polymer-coated gold nanoparticles with antibodies—synthesis and characterization. Nanomaterials. 2015 Aug 7;5(3):1297-316.
Tuan TQ, Van Son N, Dung HT, Luong NH, Thuy BT, Van Anh NT, Hoa ND, Hai NH. Preparation and properties of silver nanoparticles loaded in activated carbon for biological and environmental applications. Journal of hazardous materials. 2011 Sep 15;192(3):1321-9.
Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials. 2005 Oct 1;26(29):5898-906.
Raghav R, Srivastava S. Immobilization strategy for enhancing sensitivity of immunosensors: L-Asparagine–AuNPs as a promising alternative of EDC–NHS activated citrate–AuNPs for antibody immobilization. Biosensors and Bioelectronics. 2016 Apr 15;78:396-403.
Haghighi AH, Faghih Z, Khorasani MT, Farjadian F. Antibody conjugated onto surface modified magnetic nanoparticles for separation of HER2+ breast cancer cells. Journal of Magnetism and Magnetic Materials. 2019 Nov 15;490:165479.
Derakhshandeh K, Khaleseh F, Azandaryani AH, Mansouri K, Khazaei M. Active targeting carrier for breast cancer treatment: Monoclonal antibody conjugated epirubicin loaded nanoparticle. Journal of Drug Delivery Science and Technology. 2019 Oct 1;53:101136.
Chen LJ, Shah SS, Silangcruz J, Eller MJ, Verkhoturov SV, Revzin A, Schweikert EA. Characterization and quantification of nanoparticle–antibody conjugates on cells using C60 ToF SIMS in the event-by-event bombardment/detection mode. International Journal of Mass Spectrometry. 2011 Jun 1;303(2-3):97-102.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
